HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fiore Rx Antifungal Nail Lacquer Claims Clipped At NAD After Avoiding FTC

This article was originally published in The Rose Sheet

Executive Summary

NAD welcomes Fiore RX back to the self-regulatory process one year after referring its Fiore Rx Antifungal Nail Lacquer claims to FTC due to the company’s unresponsiveness. The review does not go favorably for the firm, which must discontinue or modify all 22 claims targeted by NAD in its inquiry for lack of substantiating evidence.

You may also be interested in...



Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim

Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.

Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim

Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.

EU Scientific Committee Reviewing Three UV Filters Against Endocrine-Disrupting Concerns

The European Commission issued requests on 4 February for updated opinions from the Scientific Committee on Consumer Safety on octocrylene, homosalate and benzophenone-3, in light of concerns that led to their listing in 2019 as “higher priority” substances used in cosmetics with endocrine-disrupting potential.

UsernamePublicRestriction

Register

RS019143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel